Minimal But Significant Improvement in Survival for Non Hepatitis C Related Adult Liver Transplant Patients Beyond the One-Year Posttransplant Mark
|
|
- Irma Blankenship
- 5 years ago
- Views:
Transcription
1 LIVER TRANSPLANTATION 16: , 2010 ORIGINAL ARTICLE Minimal But Significant Improvement in Survival for Non Hepatitis C Related Adult Liver Transplant Patients Beyond the One-Year Posttransplant Mark Geoffrey W. McCaughan, 1,2 Nicholas A. Shackel, 1,2 Simone I. Strasser, 1 Pamela Dilworth, 1 and Patrick Tang 1 1 Australian National Liver Transplant Unit, Royal Prince Alfred Hospital, University of Sydney, Sydney, Australia; and 2 Centenary Research Institute, Royal Prince Alfred Hospital, University of Sydney, Sydney, Australia on The behalf of The Australian and New Zealand Liver Transplant Study Group. Although 1-year survival rates following liver transplantation over the last 20 years may have improved, there is doubt about improvement in long-term survival. We examined survival with and without initial 12-month mortality in adult liver transplant recipients over a 20-year period. Patient and allograft survival for 3 different time periods was compared: (group 1, n ¼ 547), (group 2, n ¼ 735), and (group 3, n ¼ 749). After this, all deaths in the first 12 months of each group were removed. Patient and allograft survival was then once again compared across the 3 groups. There was significant improvement in both patient and allograft survival across the 20-year period (P < 0.001). Overall patient and allograft survival improved in non hepatitis C virus (HCV) patients but not in HCV patients. A similar comparison with deaths in the first year removed, however, showed no difference in patient survival (P ¼ 0.07) and only a marginal improvement in allograft survival (P ¼ 0.048) between the 3 time periods. When patients were divided into HCV-positive and HCV-negative groups with deaths in the first year removed, there was, however, improved patient and allograft survival in the HCV-negative group but not in the HCV-positive group. The causes of death between 1 and 5 years were then compared. There were 48 deaths in period 1, 63 in period 2, and 43 in period 3 (P ¼ not significant). There were more deaths due to cardio/cerebrovascular disease and hepatitis B virus recurrence in the first time period, but there were more deaths due to recurrent HCV and de novo malignancy in later time periods. In conclusion, although overall survival following liver transplantation in adults seems to be improving over time, the long-term results are not, particularly in HCV patients. Liver Transpl 16: , VC 2010 AASLD. Received September 1, 2008; accepted October 19, It is generally recognized that there has been improved survival over the past 20 years for patients undergoing liver transplantation. 1,2 This has been attributed to improvements in surgical techniques, immunosuppression, and anti-infective therapies that particularly benefit early survival. However, in renal transplantation, it has been realized that improved 1-year survival may not necessarily translate into improved long-term benefits. 3 This has now been recognized to be associated with what is known as chronic allograft nephropathy. Such a process is not recognized after liver transplantation with a less than 5% rate of chronic allograft rejection. 4,5 However, it has always been realized that patients who require long-term immunosuppression are at risk Abbreviations: AIH, autoimmune hepatitis; ALD, alcoholic liver disease; ANLTU, Australian National Liver Transplant Unit Sydney; ANZLTR, Australian and New Zealand Liver Transplant Registry; FHF, fulminant hepatic failure; HAT, hepatic artery thrombosis; HBV, hepatitis B virus; HCC, hepatocellular carcinoma; HCV, hepatitis C virus; NZLTU, New Zealand Liver Transplant Unit; PBC, primary biliary cirrhosis; PSC, primary sclerosing cholangitis; QLTU, Queensland Liver Transplant Unit; SALTU, South Australian Liver Transplant Unit; UNOS, United Network for Organ Sharing; VLTU, Victorian Liver Transplant Unit; WALTU, Western Australian Liver Transplant Unit. Address reprint requests to Geoffrey W. McCaughan, Royal Prince Alfred Hospital, University of Sydney, Sydney, Australia. Telephone: þ , þ , and ; FAX: þ ; g.mccaughan@centenary.usyd.edu.au DOI /lt Published online in Wiley InterScience ( VC 2010 American Association for the Study of Liver Diseases.
2 MINIMAL BUT SIGNIFICANT IMPROVEMENT IN SURVIVAL 131 of cardiovascular diseases and malignancy. 6,7 Furthermore, since the emergence in the past 10 years of recurrent hepatitis C virus (HCV) infection in the liver allograft, it has been realized that long-term results following liver transplantation are not as good as originally anticipated. 8 Doubts about improvements in long-term survival in liver transplant patients have been raised in a recent publication that examined mortality following liver transplantation over 2 consecutive 5-year periods. 9 Although overall improved survival was seen (but not in all patient diagnoses), when first 12-month mortality was censored, there was indeed no improvement in 1- to 5-year survival between the 2 periods, and this indicated no improvement in long-term outcomes. This is the only publication that has so far addressed this issue in such a way, although a brief comment in a UK analysis suggested similar findings when first 6-month mortality was censored. 10 Thus, the aim of this study was to perform a survival analysis with and without initial 12-month mortality on a different database [the Australian and New Zealand Liver Transplant Registry (ANZLTR)]. This database has prospectively gathered mortality data over a 20- year period for patients undergoing liver transplantation in Australia and New Zealand. PATIENTS AND METHODS Patient Population The ANZLTR has prospectively received mortality data from all transplant units in Australia and New Zealand since Causes of death and underlying disease indications have also been obtained. The analysis reported here includes only adult patients (>16 years) and occurred in several steps. First, overall patient and allograft survival for 3 different time periods was compared: (group1), (group 2), and (group 3). The longer period in group 1 was chosen to allow similar numbers of transplants to be compared. After this, all deaths in the first 12 months of each group were censored (removed). Patient and allograft survival was then once again compared across the 3 groups. Follow-up was in December Patients were also separated on the basis of the original disease into HCV infection and non-hcv groups. The diagnosis of HCV infection was based on HCV antibody testing. Causes of death were also compared between 1 and 5 years post liver transplantation across groups Statistical Methods All statistical analyses were performed with SPSS Univariate and multivariate analyses of covariates and Kaplan-Meier and Cox proportional hazard models on survival were conducted. The chi-square test was used to compare differences of categorical variables, and the t test was used to compare continuous variables. P < 0.05 was considered to be significant. RESULTS From 1986 to 2005, 2031 adults underwent transplantation. There were 123 second transplants and 7 third transplants, and this resulted in 2161 allografts. Between 1986 and 1994 (group 1), there were 547 patients undergoing primary transplantation; between 1995 and 2000 (group 2), there were 735; and between 2001 and 2005 (group 3), there were 749. Primary diagnoses across the 3 eras are shown in Table 1. The major shifts were an increase in HCV and hepatocellular carcinoma (HCC) and a reduction in primary biliary cirrhosis, autoimmune hepatitis, primary sclerosing cholangitis, and fulminant hepatic failure between groups 1 and 2. There was an increase in recipient and donor age across the 3 eras. Figure 1 shows patient and graft survival in the 3 time periods. There was significant improvement in both patient and allograft survival across the 20-year period (P < 0.001). This was a stepwise improvement in survival between groups 1 and 2 and subsequently between groups 2 and 3. Figure 2 shows a similar comparison with deaths in the first year removed. These data show an insignificant improvement in patient survival (P ¼ 0.072) and a marginal improvement in allograft survival (P ¼ 0.048). Figure 3 separates out HCV and non-hcv patients. Overall patient and allograft survival improved in non-hcv patients but not in HCV patients, although there seemed to be worse allograft survival in the group 2 period for HCV patients (P ¼ 0.042). Figure 4 repeats the same analysis on HCV-positive and HCV-negative patients with deaths in the first year removed. This analysis showed improved patient and allograft survival in HCV-negative patients but not in HCV patients. It should be recognized that a significant number of patients with HCV (n ¼ 470) also had a diagnosis of hepatocellular cancer (n ¼ 132). There was no difference in patient or allograft survival across the 20-year period when HCV-associated HCC was removed (Fig. 5A,B). Hence, we did not dissect out further any confounding effect of HCVrelated HCC in our analysis. It is well known the donor age may influence patient and allograft survival and that donor age increased across the time periods under study. Thus, we repeated the patient survival analysis beyond the 1- year mark with donor and recipient ages measured as confounders with Cox proportion hazard regression. The results indicate survival curves similar to those shown in Figs. 2 and 4 despite the changing variables of donor and recipient age (Fig. 6). The causes of death between 1 and 5 years were then compared between all groups. This period was chosen because of the different lengths of follow-up between each group. This meant that groups 1 and 2
3 132 MCCAUGHAN ET AL. TABLE 1. Indications for Liver Transplantation Across the Three Eras P Value : (n ¼ 547) : (n ¼ 735) : (n ¼ 749) Primary diagnosis AIH PSC PBC HBV HCV < < < HCC* 25* 95* 181* < < < FHF ALD Genetic Cryptogenic Other Age Recipient (15-67) (15-68) (16-73) < < < Donor (4-67) (6-77) (7-81) < < < (first graft) *This reflects primary diagnoses (n ¼ 10, 12, and 23) and secondary diagnoses. Figure 1. Kaplan-Meier curves showing (A) overall patient survival and (B) overall allograft survival over the 3 time periods. There was increased patient and allograft survival (P < for both). Figure 2. Kaplan-Meier curves showing (A) patient and (B) allograft survival after the removal of deaths in the first year.
4 MINIMAL BUT SIGNIFICANT IMPROVEMENT IN SURVIVAL 133 Figure 3. Kaplan-Meier curves showing overall patient survival in (A) HCV-negative and (C) HCV-positive patients and allograft survival in (B) HCV-negative and (D) HCV-positive patients. Improved survival was seen only in HCV-negative patients. had 5-year follow-up on all patients, whereas the average follow-up for group 3 patients who were alive at 12 months was 4.2 years, with 232 patients followed up to 5 years. There were 48/436 deaths in period 1, 63/641 in period 2, and 43/679 in group 3. When these were then converted into deaths per patient year of follow-up, there were no statistical differences in the number of deaths between 1 and 5 years posttransplant in the 3 groups. Tables 2 to 4 show different causes of mortality and allograft loss in the 3 time periods, with more deaths due to cardiovascular disease and recurrent malignancy in period 1 and with more de novo malignancy in period 2. With respect to causes of allograft loss in years 1 to 5, in period 1, there was more allograft loss due to hepatitis B virus (HBV), and there was less allograft loss due to HCV. There was no particular difference in the pattern of de novo malignancy across the 3 periods (Table 4). DISCUSSION This article has led to important observations about the long-term follow-up of liver transplant recipients. These observations have implications for long-term patient care. The data here show that, although there has been highly significant overall improved survival over a 20-year period, this translates into only marginally improved survival if deaths in the first year are removed from such an analysis. These observations, however, have some caveats that need to be discussed. Although overall survival has improved, this was not seen in HCV-positive patients (Fig. 3C,D). In fact, there was a tendency for worse survival in HCV-positive patients, particularly in the period. It is interesting to compare these overall survival data to those recently published from the United Network for Organ Sharing (UNOS) and European databases. 9,10 In the UNOS study, there was no improved overall survival in patients with HCV, primary sclerosing cholangitis, primary biliary cirrhosis, or acute hepatic necrosis when 2 eras ( versus ) were compared. Improved survival was seen only in patients with autoimmune hepatitis and alcoholic liver disease. We have not further separated out our non-hcv patients because of the much smaller numbers. In contrast, there has been a steady overall improvement in the European Liver Transplant Registry data. 10
5 134 MCCAUGHAN ET AL. Figure 4. Kaplan-Meier curves showing (A,C) patient and (B,D) allograft survival after the removal of deaths in the first year: (A,B) HCV-negative and (C,D) HCV-positive patients. There was improved patient and allograft survival in HCV-negative patients. Abbreviation: HCV, hepatitis C virus. Figure 5. Kaplan-Meier curves showing (A) overall patient survival and (B) overall allograft survival in HCV-positive patients without HCC. Although the aforementioned results are of interest, the main point of this study was to examine survival beyond 1 year as an endpoint to address long-term survival issues. These results show that there was no difference in survival over a 20-year period (Fig. 2A,B). However, when patients were divided into non- HCV and HCV-positive groups, there was definitely a significant improvement in non-hcv patient and allograft survival. This occurred despite an increase in donor and recipient age.
6 MINIMAL BUT SIGNIFICANT IMPROVEMENT IN SURVIVAL 135 Figure 6. Patient survival, after the removal of deaths in the first year, adjusted for recipient and donor age in all patients, HCV patients, and non-hcv patients. The data are results from Cox proportional hazard regression analysis. TABLE 2. Causes of Death (1-5 Years of Follow-Up) : : : P Value Cause of Death (n ¼ 436) (n ¼ 641) (n ¼ 679) Recurrent malignancy Graft failure Cardiovascular/cerebral Sepsis De novo malignancy Respiratory Other Total In a similar analysis of the UNOS database, there were in fact no differences in survival when deaths of the first 12 months were removed for any group, including all non-hcv groups. 9 In fact, the HCV and primary sclerosing cholangitis groups had worse allograft survival in the most recent era. This was despite shorter follow-up in the most recent group ( ). (It is obvious that some patients in this latter group had less than the full 5 years of follow-up as the study was first received for publication in 2005). As mentioned earlier, a UK study reported similar survival over 4 separate time periods from 1985 to 2003 when deaths in the first 6monthswerecensored. 11 These data are mentioned in passing in the article and are shown in a single figure. The authors used these data to estimate a 22-year median survival time post liver transplantation in adult patients surviving beyond 6 months. The European Liver Transplant Registry did not formally address this. However, if Figure 4 in that report is examined closely, it seems that overall survival was improved across different time periods by differences in 12-month survival. In contrast, the survival curves after 12 months seem to have very similar slopes. It is of interest to examine the causes of death and allograft failure between 1 and 5 years in the 3 eras. This shows that, although the death rate was the same, the causes of death were different in the 3 eras, with more cardiovascular system related deaths and recurrent HBV deaths in the earlier period versus more de novo cancer deaths in the second period. Increased de novo cancer is recognized after liver transplantation, 12 but there did not seem to be any
7 136 MCCAUGHAN ET AL. TABLE 3. Cause of Death: Graft Failure (1-5 Years of Follow-Up) P Value Cause of Death: Graft Failure : : : Rejection (chronic) HBV HCV Biliary HAT Recurrent disease Other Rejection (acute) Total TABLE 4. Cause of Death: De Novo Malignancy (1-5 Years of Follow-Up) P Value Cause of Death: De Novo Malignancy : : : Colorectal Lymphoma Lung Skin Esophagus Melanoma Larynx Ovarian Pancreas Total particular pattern concerning this in our patients. In age-matched control studies, we can expect to see increases in posttransplant lymphoproliferative disease, skin cancer, colorectal cancer, and oral malignancy in liver transplant recipients. In contrast to HBV, there was a reversed pattern, with HCV playing a significantly lesser role in the earliest period. In conclusion, the overall picture from these results is that, although overall survival seems to be improving over time, the long-term results are not, particularly in HCV patients. Thus, HCV recurrence is masking any gains from improved immunosuppression, cardiovascular risk management, and control of HBV recurrence that are seen in the non-hcv group. Whether there is in addition more de novo cancer is hard to examine as there did not seem to be any particular cancer that was more common. The results highlight the need to continue to gather long-term data on liver transplant survivors. It is clear that changing indications for transplantation in combination with changing immunosuppression make comparisons over long time periods difficult. Also, different levels of pretransplant disease severity may confound analyses. These issues have not been able to be addressed in this article as immunosuppression data and severity of liver disease were not collected in the ANZLTR. However, despite these limitations, it is heartening to see that cardiovascular deaths seem to be decreasing. However, caution remains with respect to HCV recurrence and long-term malignancy. ACKNOWLEDGMENTS In addition to the authors, the members of the Australian and New Zealand Liver Transplant Study Group are as follows: Stephen Lynch [Queensland Liver Transplant Unit (QLTU)], Jonathan Fawcett (QLTU), Robert Jones [Victorian Liver Transplant Unit (VLTU)], Peter Angus (VLTU), Michael Fink (VLTU), Paul Gow (VLTU), Robert Padbury [South Australian Liver Transplant Unit (SALTU)], John Chen (SALTU), Gary Jeffrey [Western Australian Liver Transplant
8 MINIMAL BUT SIGNIFICANT IMPROVEMENT IN SURVIVAL 137 Unit (WALTU)], Luc Delrievere (WALTU), Gerry McQuillan (WALTU), Stephen Munn [New Zealand Liver Transplant Unit (NZLTU)], Ed Gane (NZLTU), John McCall (NZLTU), Debbie Verran [Australian National Liver Transplant Unit Sydney (ANLTU)], Michael Crawford (ANLTU), and James Gallagher (ANLTU). Glenda Balderson is manager of the Australian and New Zealand Liver Transplant Database. REFERENCES 1. Evans IV, Belle SH. U.S. trends in liver transplantation, 1988 to In: Bussuttil W, Klintmalm G, eds. Transplantation of the Liver. 2nd ed. Philadelphia, PA: Elsevier Saunders; pp Jain A, Reyer J, Kashyap R, et al. Long-term survival after liver transplantation in 4,000 consecutive patients at a single center. Ann Surg 2000;232: Meier-Kriesche HU, Schold JD, Srinivas TR, Kaplan B. Lack of improvement in renal allograft survival despite a marked decrease in acute rejection rates over the most recent era. Am J Transplant 2004;4: Demetris A, Adams D, Bellamy C, Blakolmer K, Clouston A, Dhillon AP, et al. Update of the International Banff Schema for Liver Allograft Rejection: working recommendations for the histopathologic staging and reporting of chronic rejection. An international panel. Hepatology 2000;31: Pirsch JD, Kalayoglu M, Hafez GR, D Alessandro AM, Sollinger HW, Belzer FD. Evidence that the vanishing bile duct syndrome is vanishing. Transplantation 1990; 49: Oo YH, Gunson BK, Lancashire RJ, Cheng KK, Neuberger JM. Incidence of cancers following orthotopic liver transplantation in a single center: comparison with national cancer incidence rates for England and Wales. Transplantation 2005;80: Sheiner PA, Magliocca JF, Bodian CA, Kim-Schluger L, Altaca G, Guarrera JV, et al. Long-term medical complications in patients surviving > or ¼ 5 years after liver transplant. Transplantation 2000;69: Berenguer M, Prieto M, San Juan F, Rayón JM, Martinez F, Carrasco D, et al. Contribution of donor age to the recent decrease in patient survival among HCV-infected liver transplant recipients. Hepatology 2002;36: Futagawa Y, Terasaki PI, Waki K, Cai J, Gjertson DW. No improvement in long-term liver transplant graft survival in the last decade: an analysis of the UNOS data. Am J Transplant 2006;6: Adam R, McMaster P, O Grady JG, et al. Evolution of liver transplantation in Europe: report of the European Liver Transplant Registry. Liver Transpl 2003;9: Barber K, Blackwell J, Collett D, Neuberger J. Life expectancy of adult liver allograft recipients in the UK. Gut 2007;56: Forman LM, Lewis JD, Berlin JA, Feldman HI, Lucey MR. The association between hepatitis C infection and survival after orthotopic liver transplantation. Gastroenterology 2002;122:
What Is the Real Gain After Liver Transplantation?
LIVER TRANSPLANTATION 15:S1-S5, 9 AASLD/ILTS SYLLABUS What Is the Real Gain After Liver Transplantation? James Neuberger Organ Donation and Transplantation, NHS Blood and Transplant, Bristol, United Kingdom;
More informationDeath in patients waiting for liver transplantation. Liver Transplant Recipient Selection: MELD vs. Clinical Judgment
ORIGINAL ARTICLES Liver Transplant Recipient Selection: MELD vs. Clinical Judgment Michael A. Fink, 1,2 Peter W. Angus, 1 Paul J. Gow, 1 S. Roger Berry, 1,2 Bao-Zhong Wang, 1,2 Vijayaragavan Muralidharan,
More informationAUSTRALIA & 27TH. Melbourne
AUSTRALIA & NEW ZEALAND Brisbane Perth Adelaide Sydney Melbourne Auckland N e w Z e a l a n d F r o m t h e C o m b i n e d R e g i s t r i e s o f t h e A u s t r a l i a n a n d N e w Z e a l a n d L
More informationThe Effect of HLA Class I (A and B) and Class II (DR) Compatibility on Liver Transplantation Outcomes: An Analysis of the OPTN Database
LIVER TRANSPLANTATION 12:652-658, 2006 ORIGINAL ARTICLE The Effect of HLA Class I (A and B) and Class II (DR) Compatibility on Liver Transplantation Outcomes: An Analysis of the OPTN Database Victor Navarro,
More informationLiver Transplantation for Alcoholic Liver Disease in the United States: 1988 to 1995
Liver Transplantation for Alcoholic Liver Disease in the United States: 1988 to 1995 Steven H. Belle, Kimberly C. Beringer, and Katherine M. Detre T he Scientific Liver Transplant Registry (LTR) was established
More informationPAPER. Liver Transplant for Hepatitis C Virus. Effect of Using Older Donor Grafts on Short- and Medium-Term Survival
PAPER Liver Transplant for Hepatitis C Virus Effect of Using Older Donor Grafts on Short- and Medium-Term Survival M. B. Majella Doyle, MD; Christopher D. Anderson, MD; Neeta Vachharajani, MD; Jeffrey
More informationLiver Transplantation in Australia and New Zealand
TRANSPLANT INTERNATIONAL Liver Transplantation in Australia and New Zealand Geoffrey W. McCaughan 1-3 and Stephen R. Munn 4,5 1 Australian National Liver Transplantation Unit and 2 AW Morrow Gastroenterology
More informationFrequency and Outcomes of Liver Transplantation for Nonalcoholic Steatohepatitis in the United States
GASTROENTEROLOGY 2011;141:1249 1253 Frequency and Outcomes of Liver Transplantation for Nonalcoholic Steatohepatitis in the United States MICHAEL R. CHARLTON,* JUSTIN M. BURNS, RACHEL A. PEDERSEN, KYMBERLY
More informationPredictors of cardiac allograft vasculopathy in pediatric heart transplant recipients
Pediatr Transplantation 2013: 17: 436 440 2013 John Wiley & Sons A/S. Pediatric Transplantation DOI: 10.1111/petr.12095 Predictors of cardiac allograft vasculopathy in pediatric heart transplant recipients
More informationLiver Transplant Pathology a general view
Liver Transplant Pathology a general view Dr S E Davies Addenbrooke s Hospital Cambridge University Hospitals NHS Trust ACP/BSG Meeting Leeds 2012 Liver transplantation When and where? Who and why? How?
More informationLiver Transplantation: The End of the Road in Chronic Hepatitis C Infection
University of Massachusetts Medical School escholarship@umms UMass Center for Clinical and Translational Science Research Retreat 2012 UMass Center for Clinical and Translational Science Research Retreat
More informationPOST TRANSPLANT OUTCOMES IN PSC
POST TRANSPLANT OUTCOMES IN PSC Kidist K. Yimam, MD Medical Director, Autoimmune Liver Disease Program Division of Hepatology and Liver Transplantation California Pacific Medical Center (CPMC) PSC Partners
More informationORIGINAL ARTICLE. Eric F. Martin, 1 Jonathan Huang, 3 Qun Xiang, 2 John P. Klein, 2 Jasmohan Bajaj, 4 and Kia Saeian 1
LIVER TRANSPLANTATION 18:914 929, 2012 ORIGINAL ARTICLE Recipient Survival and Graft Survival are Not Diminished by Simultaneous Liver-Kidney Transplantation: An Analysis of the United Network for Organ
More informationORIGINAL ARTICLE. Received April 30, 2007; accepted June
LIVER TRANSPLANTATION 13:1405-1413, 2007 ORIGINAL ARTICLE Human Leukocyte Antigen and Adult Living- Donor Liver Transplantation Outcomes: An Analysis of the Organ Procurement and Transplantation Network
More informationAustralia & New Zealand Pancreas. Transplant Registry Report
Australia & New Zealand Pancreas Transplant Registry Report 1984-2007 This report is a compilation of data provided by the five current Pancreas transplant units in Australia and New Zealand: Auckland
More informationLong-Term Renal Allograft Survival in the United States: A Critical Reappraisal
American Journal of Transplantation 2011; 11: 450 462 Wiley Periodicals Inc. C 2010 The Authors Journal compilation C 2010 The American Society of Transplantation and the American Society of Transplant
More informationLiver transplantation is the only hope for patients with terminal. Indication and Prognosis of Liver Transplantation. Abstract
Indication and Prognosis of Liver Transplantation Jae Won Joh, M.D. Department of General Surgery Sungkyunkwan University School of Medicine Samsung Medical Center E mail: jwjoh@smc.samsung.co.kr Abstract
More informationLong-term Outcomes After Third Liver Transplant
ArtıcLe Long-term Outcomes After Third Liver Transplant C. Burcin Taner, 1 Deniz Balci, 1 Darrin L. Willingham, 1 Andrew P. Keaveny, 1 Barry G. Rosser, 1 Juan M. Canabal, 1 Timothy S. J. Shine, 2 Denise
More informationHow to improve long term outcome after liver transplantation?
How to improve long term outcome after liver transplantation? François Durand Hepatology & Liver Intensive Care University Paris Diderot INSERM U1149 Hôpital Beaujon, Clichy PHC 2018 www.aphc.info Long
More informationRecurrence of hepatitis C virus (HCV) after orthotopic. Poor Survival After Liver Retransplantation: Is Hepatitis C to Blame?
RAPID COMMUNICATION Poor Survival After Liver Retransplantation: Is Hepatitis C to Blame? Kymberly D.S. Watt, Elizabeth R. Lyden, and Timothy M. McCashland Data from 1990 to 1996 suggest that the prevalence
More informationORIGINAL ARTICLE. Hung-Tien Kuo, 1,2 Erik Lum, 1 Paul Martin, 3 and Suphamai Bunnapradist ORIGINAL ARTICLE
ORIGINAL ARTICLE Effect of Diabetes and Acute Rejection on Liver Transplant Outcomes: An Analysis of the Organ rocurement and Transplantation Network/United Network for Organ Sharing Database Hung-Tien
More informationSurvival of Liver Transplant Recipients With Hemochromatosis in the United States
GASTROENTEROLOGY 2007;133:489 495 Survival of Liver Transplant Recipients With Hemochromatosis in the United States LEI YU*, and GEORGE N. IOANNOU*, *Division of Gastroenterology, Department of Medicine
More informationIncidence of Rejection in Renal Transplant Surgery in the LVHN Population Leading to Graft Failure: 6 Year Review
Incidence of Rejection in Renal Transplant Surgery in the LVHN Population Leading to Graft Failure: 6 Year Review Jessica Ludolph 1 Lynsey Biondi, MD 1,2 and Michael Moritz, MD 1,2 1 Department of Surgery,
More informationRemoving Patients from the Liver Transplant Wait List: A Survey of US Liver Transplant Programs
LIVER TRANSPLANTATION 14:303-307, 2008 ORIGINAL ARTICLE Removing Patients from the Liver Transplant Wait List: A Survey of US Liver Transplant Programs Kevin P. Charpentier 1 and Arun Mavanur 2 1 Rhode
More informationLiver Transplantation for Biliary Atresia: 19-Year, Single-Center Experience
Liver Transplantation for Biliary Atresia: 19-Year, Single-Center Experience L Thomas Chin 1, Anthony M D Alessandro 1, Stuart J Knechtle 1, Luis A Fernandez 1, Glen Leverson 1, Robert H Judd 2, Elizabeth
More informationSurvival After Orthotopic Liver Transplantation: The Impact of Antibody Against Hepatitis B Core Antigen in the Donor
LIVER TRANSPLANTATION 15:1343-1350, 2009 ORIGINAL ARTICLE Survival After Orthotopic Liver Transplantation: The Impact of Antibody Against Hepatitis B Core Antigen in the Donor Lei Yu, 1-3 Thomas Koepsell,
More informationTransplant Hepatology
Transplant Hepatology Certification Examination Blueprint Purpose of the exam The exam is designed to evaluate the knowledge, diagnostic reasoning, and clinical judgment skills expected of the certified
More informationLIVER TRANSPLANTATION FOR OVERLAP SYNDROMES OF AUTOIMMUNE LIVER DISEASES
LIVER TRANSPLANTATION FOR OVERLAP SYNDROMES OF AUTOIMMUNE LIVER DISEASES No conflict of interest Objectives Introduction Methods Results Conclusions Objectives Introduction Methods Results Conclusions
More informationDonor-Transmitted, Donor-Derived, and De Novo Cancer After Liver Transplant
Lecture Donor-Transmitted, Donor-Derived, and De Novo Cancer After Liver Transplant Jeremy R. Chapman, 1 Stephen V. Lynch 2 Abstract Cancer is the third most common cause of death (after cardiovascular
More informationE nd stage liver disease due to hepatitis C virus infection
248 LIVER DISEASE Advancing donor liver age and rapid fibrosis progression following transplantation for hepatitis C M Wali, R F Harrison, P J Gow, D Mutimer... Gut 2002;51:248 252 See end of article for
More informationEffect of Calcineurin Inhibitors on Survival and Histologic Disease Severity in HCV-Infected Liver Transplant Recipients
LIVER TRANSPLANTATION 12:762-767, 2006 ORIGINAL ARTICLE Effect of Calcineurin Inhibitors on Survival and Histologic Disease Severity in HCV-Infected Liver Transplant Recipients Marina Berenguer, 1 Victoria
More informationHwm YI Yoo, * Ernest0 Molmenti, ' and PuulJ Tbuluvutb"
The Effect of Donor Body Mass Index on Primary Nonfunction, Retransplantation Rate, and Early and Patient Survival After Liver Transplantation Hwm YI Yoo, * Ernest0 Molmenti, ' and PuulJ Tbuluvutb" Previous
More informationCASE 1 Plasma Cell Infiltrates: Significance in post liver transplantation and in chronic liver disease
CASE 1 Plasma Cell Infiltrates: Significance in post liver transplantation and in chronic liver disease Maria Isabel Fiel, M.D. The Mount Sinai Medical Center New York, New York Case A 57 yo man, 7 months
More informationLate Protocol Liver Biopsies in the Liver Allograft: A Neglected Investigation?
LIVER TRANSPLANTATION 15:931-938, 2009 ORIGINAL ARTICLE Late Protocol Liver Biopsies in the Liver Allograft: A Neglected Investigation? George Mells, 1 Caroline Mann, 1 Stefan Hubscher, 2 and James Neuberger
More informationDe novo malignancy occurs more commonly after. Long-term Probability of and Mortality From De Novo Malignancy After Liver Transplantation
GASTROENTEROLOGY 2009;137:2010 2017 Long-term Probability of and Mortality From De Novo Malignancy After Liver Transplantation KYMBERLY D. S. WATT,* RACHEL A. PEDERSEN, WALTER K. KREMERS, JULIE K. HEIMBACH,
More informationLiver transplant: what is left after the viruses
Riunione Monotematica A.I.S.F. 2016 The Future of Liver Disease: Beyond HCV is there a Role for Hepatologist? Milan 15 th 2016 Liver transplant: what is left after the viruses Stefano Ginanni Corradini
More informationHepatitis After Liver Transplantation: The Role of the Known and Unknown Viruses
Hepatitis After Liver Transplantation: The Role of the Known and Unknown Viruses Mario G. Pessoa,*00 Norah A. Terrault,*00 Linda D. Ferrell, Jill Detmer, Janice Kolberg, Mark L. Collins, Maurene Viele,
More informationDoes the Banff Rejection Activity Index Predict Outcome in Patients With Early Acute Cellular Rejection Following Liver Transplantation?
LIVER TRANSPLANTATION 12:1144-1151, 2006 ORIGINAL ARTICLE Does the Banff Rejection Activity Index Predict Outcome in Patients With Early Acute Cellular Rejection Following Liver Transplantation? Barbara
More informationThe Effect of Liver Transplantation on Autonomic Dysfunction in Patients with End-Stage Liver Disease
LIVER TRANSPLANTATION 14:235-239, 2008 ORIGINAL ARTICLE The Effect of Liver Transplantation on Autonomic Dysfunction in Patients with End-Stage Liver Disease Elizabeth J. Carey, Manjushree Gautam, 3 Timothy
More informationAustralia & New Zealand Pancreas. Transplant Registry Report
Australia & New Zealand Pancreas Transplant Registry Report 1984-2009 This report is a compilation of data provided by the three current Pancreas transplant units in Australia and New Zealand: Auckland
More informationLiver Transplant: Alcoholic liver disease as first indication
Monotematica AISF The future of liver disease: beyond HCV there is a role for hepatologist? Milano, 13-15 Ottobre 2016 Liver Transplant: Alcoholic liver disease as first indication Giacomo Germani Multivisceral
More informationFor the past two decades, the number of patients
When Shouldn t We Retransplant? Michael A. Zimmerman and R. Mark Ghobrial Key Points 1. In the setting of early graft failure after primary transplantation, orthotopic liver retransplantation (re-olt)
More information11 th Banff Conference on Allograft Pathology - An Update
11 th Banff Conference on Allograft Pathology - An Update Stefan Hübscher, School of Cancer Sciences, University of Birmingham Dept of Cellular Pathology, Queen Elizabeth Hospital, Birmingham Enghien les
More informationThe Norwegian PSC Research Center Biobank
The Norwegian PSC Research Center Biobank Trine Folseraas Norwegian PSC Research Center, Department of Transplantation Medicine, Division of Surgery, Inflammatory Medicine and Transplantation, Oslo University
More informationVictorian Liver Transplant Unit. Annual Report Page 1
Victorian Liver Transplant Unit Annual Report 2017-2018 Page 1 Contents Preface... 3 Report Purpose... 3 2017/18 Summary... 4 Total Transplant Activity... 5 2017/18 Activity Summary... 5 2017/18 Transplant
More informationPeri-operative challenges and long-term outcomes in liver transplantation for polycystic liver disease
DOI:10.1111/j.1477-2574.2012.00579.x HPB ORIGINAL ARTICLE Peri-operative challenges and long-term outcomes in liver transplantation for polycystic liver disease Roberto Gedaly, Paige Guidry, Daniel Davenport,
More informationHistopathological Causes of Late Liver Allograft Dysfunction: Analysis at a Single Institution
The Korean Journal of Pathology 2013; 47: 21-27 ORIGINAL ARTICLE Histopathological Causes of Late Liver Allograft Dysfunction: Analysis at a Single Institution Eun Shin Ji Hoon Kim 1 Eunsil Yu 1 Department
More informationThe pediatric end-stage liver disease (PELD) score
Selection of Pediatric Candidates Under the PELD System Sue V. McDiarmid, 1 Robert M. Merion, 2 Dawn M. Dykstra, 2 and Ann M. Harper 3 Key Points 1. The PELD score accurately predicts the 3 month probability
More informationViral Hepatitis And Liver Transplantation
Viral Hepatitis And Liver Transplantation Dr.Zeki KARASU Ege University Medical School Dep. Gastroenterology Hepatitis B 3-7 10 % HBV infection in liver transplant recipients, in western countries. 120
More informationType of intervention Other: transplantation. Economic study type Cost-utility analysis.
Midterm cost-effectiveness of the liver transplantation program of England and Wales for three disease groups Longworth L, Young T, Buxton M J, Ratcliffe J, Neuberger J, Burroughs A, Bryan S Record Status
More informationThe Effect of Donor Race on the Survival of Black Americans Undergoing Liver Transplantation for Chronic Hepatitis C
LIVER TRANSPLANTATION 15:1126-1132, 2009 ORIGINAL ARTICLE The Effect of Donor Race on the Survival of Black Americans Undergoing Liver Transplantation for Chronic Hepatitis C Phillip S. Pang, 1,2 * Ahmad
More informationPediatric Liver Transplantation Outcomes in Korea
ORIGINAL ARTICLE Cell Therapy & Organ Transplantation http://dx.doi.org/6/jkms.8..4 J Korean Med Sci 0; 8: 4-47 Pediatric Liver Transplantation Outcomes in Korea Jong Man Kim,, * Kyung Mo Kim,, * Nam-Joon
More informationErratum to: Int J Hematol (2014) 99: DOI /s
Int J Hematol (216) 13:725 729 DOI 1.17/s12185-16-1987-1 ERRATUM Erratum to: Prolonged thrombocytopenia after living donor liver transplantation is a strong prognostic predictor irrespective of history
More information2017 BANFF-SCT Joint Scientific Meeting. Personalized Medicine in Liver Transplantation
2017 BANFF-SCT Joint Scientific Meeting Personalized Medicine in Liver Transplantation Miquel Navasa Liver Transplant Unit. Hospital Clínic. Barcelona. Barcelona, March 2017 Disclosures Consultant for
More informationCirrhosis secondary to chronic hepatitis C viral
Effect of Alcoholic Liver Disease and Hepatitis C Infection on Waiting List and Posttransplant Mortality and Transplant Survival Benefit Michael R. Lucey, 1 Douglas E. Schaubel, 2,3 Mary K. Guidinger,
More informationCHAPTER 10 CANCER REPORT. Jeremy Chapman. and. Angela Webster
CHAPTER 10 CANCER REPORT Jeremy Chapman and Angela Webster CANCER REPORT ANZDATA Registry 2004 Report This report summarises the cancer (excluding nonmelanocytic skin cancer) experience of patients treated
More informationRAPID COMMUNICATION Preexisting malignancy is considered a relative contrain- dication to orthotopic liver transplantation (OLT) be-
RAPID COMMUNICATION Successful Outcome of Orthotopic Liver Transplantation in s With Preexisting Malignant States Sanjiv Saigal, Suzanne Norris, Parthi Srinivasan, Paolo Muiesan, Mohamed Rela, Nigel Heaton,
More information/03/ /0 TRANSPLANTATION Vol. 75, , No. 7, April 15, 2003 Copyright 2003 by Lippincott Williams & Wilkins, Inc.
0041-1337/03/7507-1020/0 TRANSPLANTATION Vol. 75, 1020 1025, No. 7, April 15, 2003 Copyright 2003 by Lippincott Williams & Wilkins, Inc. Printed in U.S.A. THE ABSENCE OF CHRONIC REJECTION IN PEDIATRIC
More informationJ Am Soc Nephrol 14: , 2003
J Am Soc Nephrol 14: 208 213, 2003 Kidney Allograft and Patient Survival in Type I Diabetic Recipients of Cadaveric Kidney Alone Versus Simultaneous Pancreas/Kidney Transplants: A Multivariate Analysis
More informationHPB ORIGINAL ARTICLE. Abstract. Keywords. Correspondence. Introduction
DOI:1111/j.1477-2574.2009.00022.x HPB ORIGINAL ARTICLE Poorer survival in patients whose explanted hepatocellular carcinoma (HCC) exceeds Milan or UCSF Criteria. An analysis of liver transplantation in
More informationLiver Transplantation By: Kay R. Brown, CLCP
Liver Transplantation By: Kay R. Brown, CLCP Dr. Jeffrey Crippin, Director of Hepatology at the Baylor Institute of Transplantation in Dallas, Texas outlined during the Transplantation '97 seminar the
More informationQuantification of the Early Risk of Death in Elderly Kidney Transplant Recipients
Wiley Periodicals Inc. C Copyright 2012 The American Society of Transplantation and the American Society of Transplant Surgeons Quantification of the Early Risk of Death in Elderly Kidney Transplant Recipients
More informationWhat s new in liver transplantation? Romil Saxena, MD, FRCPath (UK) Indiana University School of Medicine, Indianapolis
What s new in liver transplantation? Romil Saxena, MD, FRCPath (UK) Indiana University School of Medicine, Indianapolis A combination of improved surgical techniques, donor organ preservation, selection
More informationAutoimmune Hepatitis: Defining the need for Liver Transplantation
Autoimmune Hepatitis: Defining the need for Liver Transplantation Michael A Heneghan, MD, MMedSc, FRCPI. Institute of Liver Studies, King s College Hospital, London Outline Autoimmune Hepatitis Background
More informationAn analysis of tacrolimus-related complications in the first 30 days after liver transplantation
CLINICAL SCIENCE An analysis of tacrolimus-related complications in the first 30 days after liver transplantation Lucas Souto Nacif, André Ibrahim David, Rafael Soares Pinheiro, Marcio Augusto Diniz, Wellington
More informationInduction Immunosuppression With Rabbit Antithymocyte Globulin in Pediatric Liver Transplantation
LIVER TRANSPLANTATION 12:1210-1214, 2006 ORIGINAL ARTICLE Induction Immunosuppression With Rabbit Antithymocyte Globulin in Pediatric Liver Transplantation Ashesh Shah, 1 Avinash Agarwal, 1 Richard Mangus,
More informationPeritransplant Pancreatitis: A Marker of High Mortality and Graft Failure in Liver Transplant Patients
ORIGINAL ARTICLE RUSSELL ET AL. Peritransplant Pancreatitis: A Marker of High Mortality and Graft Failure in Liver Transplant Patients Tara A. Russell, 1 Sarah Park, 2 Vatche G. Agopian, 3 Ali Zarrinpar,
More informationTHE NORDIC LIVER TRANSPLANT REGISTRY ANNUAL REPORT Report prepared by Kristian Bjøro
THE NORDIC LIVER TRANSPLANT REGISTRY ANNUAL REPORT 2 Report prepared by Kristian Bjøro March 21 1 Nordic liver transplant registry - 2 As of December 31.2 the registry comprised data on 2167 patients of
More informationResearch Article A Decade of Experience Using mtor Inhibitors in Liver Transplantation
Transplantation Volume 2011, Article ID 913094, 7 pages doi:10.1155/2011/913094 Research Article A Decade of Experience Using mtor Inhibitors in Liver Transplantation Jeffrey Campsen, 1, 2 Michael A. Zimmerman,
More informationCOMPARISON OF THE SURVIVAL OF SHIPPED AND LOCALLY TRANSPLANTED CADAVERIC RENAL ALLOGRAFTS
COMPARISON OF THE SURVIVAL OF SHIPPED AND LOCALLY TRANSPLANTED CADAVERIC RENAL ALLOGRAFTS A COMPARISON OF THE SURVIVAL OF SHIPPED AND LOCALLY TRANSPLANTED CADAVERIC RENAL ALLOGRAFTS KEVIN C. MANGE, M.D.,
More informationSupplementary Digital Content
Geissler et al: Sirolimus and Hepatocellular Carcinoma in Liver Transplantation Page 1 of 10 Supplementary Digital Content Supplementary Table 1. Surgical procedures used Total Transplant technique Piggy
More informationLong term liver transplant management
Long term liver transplant management Dr Bill Griffiths Cambridge Liver Unit Royal College of Physicians 5.7.17 Success of Liver Transplantation Current survival, 1 st elective transplant: 1 yr survival
More informationORIGINAL ARTICLE. Summary
Transplant International ISSN 0934-0874 ORIGINAL ARTICLE Thrombotic and nonthrombotic hepatic artery complications in adults and children following primary liver transplantation with long-term follow-up
More informationImmunosuppression status of liver transplant recipients with hepatitis C affects biopsy-proven acute rejection
pissn 2287-2728 eissn 2287-285X Original Article Clinical and Molecular Hepatology 2016;22:366-371 Immunosuppression status of liver transplant recipients with hepatitis C affects biopsy-proven acute rejection
More informationExperience with Liver Transplantation in patients over 65 years of Age at the Hospital Pablo Tobón Uribe in Medellin, Colombia from 2004 to 2010
Original articles Experience with Liver Transplantation in patients over 65 years of Age at the Hospital Pablo Tobón Uribe in Medellin, Colombia from 2004 to 2010 Octavio Muñoz, MD, 1 Laura Ovadía, MD,
More informationHepatic Retransplantation in Cholestatic Liver Disease: Impact of the Interval to Retransplantation on Survival and Resource Utilization
Hepatic Retransplantation in Cholestatic Liver Disease: Impact of the Interval to Retransplantation on Survival and Resource Utilization W. RAY KIM, 1 RUSSELL H. WIESNER, 1 JOHN J. POTERUCHA, 1 TERRY M.
More informationBanff Schema for Grading Liver Allograft Rejection: Utility in Clinical Practice
Banff Schema for Grading Liver Allograft Rejection: Utility in Clinical Practice Donald G. Ormonde,* W. Bastiaan de Boer, Anthony Kierath, Roger Bell, Keith B. Shilkin, Anthony K. House, Gary P. Jeffrey,*,
More informationLiver grafts for transplantation from donors with diabetes: an analysis of the Scientific Registry of Transplant Recipients database
Title Liver grafts for transplantation from donors with diabetes: an analysis of the Scientific Registry of Transplant Recipients database Author(s) Zheng, J; Xiang, J; Zhou, J; Li, Z; Hu, Z; Lo, CM; Wang,
More informationChronic rejection (CR) is one of the causes of late liver
Accuracy of Bile Duct Changes for the Diagsis of Chronic Liver Allograft Rejection: Reliability of the 1999 Banff Schema Mylène Sebagh, 1 Karin Blakolmer, 1 Bru Falissard, 3 Bru Roche, 2 Jean-Francois
More informationLimiting Hepatitis C Virus Progression in Liver Transplant Recipients Using Sirolimus-Based Immunosuppression
Wiley Periodicals Inc. C Copyright 2011 The American Society of Transplantation and the American Society of Transplant Surgeons Limiting Hepatitis C Virus Progression in Liver Transplant Recipients Using
More informationUK Liver Transplant Audit
November 2012 UK Liver Transplant Audit In patients who received a Liver Transplant between 1 st March 1994 and 31 st March 2012 ANNUAL REPORT Advisory Group for National Specialised Services Prepared
More informationSeronegative (also known as non-a, non-b or non-a,
Outcomes Following Liver Transplantation for Seronegative Acute Liver Failure: Experience During a 12-Year Period With More Than 100 Patients Alan J. Wigg, 1,2 Bridget K. Gunson, 1 and David J. Mutimer
More informationRetransplantation for Recurrent Hepatitis C in the MELD Era: Maximizing Utility
Retransplantation for Recurrent Hepatitis C in the MELD Era: Maximizing Utility James R. Burton, Jr., 1,2 Amnon Sonnenberg, 1,2 and Hugo R. Rosen 1,2 Key Points 1. Retransplantation (re-lt) for hepatitis
More informationGood outcomes of liver transplantation for hepatitis C at a low volume centre
Good outcomes of liver transplantation for hepatitis C., 2016; 15 (2): 207-214 ORIGINAL ARTICLE March-April, Vol. 15 No. 2, 2016: 207-214 207 The Official Journal of the Mexican Association of Hepatology,
More informationEffect of donor-specific antibodies and panel reactive antibodies in living donor liver transplant recipients
ORIGINAL ARTICLE pissn 2288-6575 eissn 2288-6796 http://dx.doi.org/1.4174/astr.215.88.2.1 Annals of Surgical Treatment and Research Effect of donor-specific antibodies and panel reactive antibodies in
More informationAustralia & New Zealand Pancreas. Transplant Registry Report Inquiries or comments should be directed to the secretariat at:
Australia & New Zealand Pancreas Transplant Registry Report 1984-2013 This report is a compilation of data provided by the four current Pancreas transplant units in Australia and New Zealand: Auckland
More informationThe future of liver transplantation for viral hepatitis
The future of liver transplantation for viral hepatitis François Durand Hepatology & Liver Intensive Care Hospital Beaujon, Clichy University Paris Diderot France Liver transplantation in France 2013:
More informationResearch Article New Onset Diabetes Mellitus in Living Donor versus Deceased Donor Liver Transplant Recipients: Analysis of the UNOS/OPTN Database
Transplantation Volume 2013, Article ID 269096, 7 pages http://dx.doi.org/10.1155/2013/269096 Research Article New Onset Diabetes Mellitus in Living Donor versus Deceased Donor Liver Transplant Recipients:
More informationEvaluating HIV Patient for Liver Transplantation. Marion G. Peters, MD Professor of Medicine University of California San Francisco USA
Evaluating HIV Patient for Liver Transplantation Marion G. Peters, MD Professor of Medicine University of California San Francisco USA Slide 2 ESLD and HIV Liver disease has become a major cause of death
More informationA %; 45%) , 60%; 3-4, 54%; 5-6, 57% [ P
Long-Term Outcome of Human Leukocyte Antigen Mismatching in Liver Transplantation: Results of the National Institute of Diabetes and Digestive and Kidney Diseases Liver Transplantation Database Vijayan
More informationLiver Transplantation Using Donation After Cardiac Death Donors: Long-Term Follow-Up from a Single Center
American Journal of Transplantation 2009; 9: 773 781 Wiley Periodicals Inc. C 2009 The Authors Journal compilation C 2009 The American Society of Transplantation and the American Society of Transplant
More informationLiver Transplantation
1 Liver Transplantation Department of Surgery Yonsei University Wonju College of Medicine Kim Myoung Soo M.D. ysms91@wonju.yonsei.ac.kr http://gs.yonsei.ac.kr History Development of Liver transplantation
More informationCurrently, the leading indication for liver transplantation
ORIGINAL ARTICLES Severe Recurrent Hepatitis C After Liver Retransplantation for Hepatitis C Virus Related Graft Cirrhosis Marina Berenguer, * Martín Prieto, * Antonio Palau, * José M. Rayón, Domingo Carrasco,
More informationSupervivencia a 5 años de Pacientes Coinfectados por VHC-VIH Trasplantados Hepáticos: un Estudio de Casos y Controles
I Congreso de GESIDA Madrid, 21-24 de Octubre del 2009. Supervivencia a 5 años de Pacientes Coinfectados por VHC-VIH Trasplantados Hepáticos: un Estudio de Casos y Controles José M. Miró, 1 Miguel Montejo,
More informationThe Nordic Liver Transplant Registry (NLTR) Annual report 2010
The Nordic Liver Transplant Registry (NLTR) Annual report 2010 Report prepared by Tom H. Karlsen April 2011 Responsible contact persons: Scandiatransplant Denmark - Århus; Frank Pedersen TX Denmark - Copenhagen;
More informationIncidence and Risk Factors of HCV Recurrence after Living Donor Liver Transplantation
Incidence and Risk Factors of HCV Recurrence after Living Donor Liver Transplantation Mohsen M. Maher 1, Mahmoud S. El-Meteini 2, Mohamed F. Abd Al-Ghaffar 2, Tark M. Yousef, Maha M. Hussein 1, Ahmed I.
More informationPrimary sclerosing cholangitis (PSC) is a chronic
Predicting Clinical and Economic Outcomes After Liver Transplantation Using the Mayo Primary Sclerosing Cholangitis Model and Child-Pugh Score Jayant A. Talwalkar, * Eric Seaberg, W. Ray Kim, * and Russell
More informationImpact of Chronic Liver Disease and Cirrhosis on Health Utilities Using SF-6D and the Health Utility Index
LIVER TRANSPLANTATION 14:321-326, 2008 ORIGINAL ARTICLE Impact of Chronic Liver Disease and Cirrhosis on Health Utilities Using SF-6D and the Health Utility Index Amy A. Dan, 1,2 Jillian B. Kallman, 1,2
More informationShould Pediatric Patients Wait for HLA-DR-Matched Renal Transplants?
American Journal of Transplantation 2008; 8: 2056 2061 Wiley Periodicals Inc. C 2008 The Authors Journal compilation C 2008 The American Society of Transplantation and the American Society of Transplant
More informationOrgan allocation for liver transplantation: Is MELD the answer? North American experience
Organ allocation for liver transplantation: Is MELD the answer? North American experience Douglas M. Heuman, MD Virginia Commonwealth University Richmond, VA, USA March 1998: US Department of Health and
More information